

Intervacc presents results of new study – their vaccine Strangvac® protects horses against strangles even at a low dose

Intervacc recently completed a study where the primary goals were to establish a suitable level of antigens in Strangvac and to assess the efficacy after two intramuscular immunisations.

Ponies were vaccinated intramuscularly with three different levels of antigens and then subjected to experimental infection with *Streptococcus equi*, the causative agent of strangles.

According to CRO Jan-Ingmar Flock the results are very encouraging in that it was found that a very low dose of antigen led to the same level of protection as using ten times higher. This finding has a great impact on the cost of vaccine production. For the coming studies, where the duration of protection will be investigated, the dosage will be based on these novel findings.

Reduced clinical signs were found in approximately 60% of the ponies. In the studies to come, a third immunisation will be given and an improved level of protection is then anticipated.

As a positive control, a group of five ponies were vaccinated following our previous procedure. Here a combined route of intranasal and subcutaneous injections was used. All vaccinated ponies had clearly reduced or no clinical signs of infection as compared with the non-vaccinated control group. The study confirms previous good results concerning the efficacy of Strangvac.

For more information please contact

Anders Franklin, CEO Intervacc, +46(0) 8 120 10 601

Intervacc AB is a Swedish company within Life Science. The development is focused on vaccines within animal health. The company is in the final stage of many years of research and development of the vaccine Strangvac against the worldwide horse disease strangles.